KNSA
Kiniksa Pharmaceuticals International, plc
Set alert
92.24 USD -5.32 -5.45%
91.25 Day range 98.48
37.01 52-week range 97.56
- YTD
- +123.61%
- 1 year
- +147.36%
- Open
- 97.60
- Prev close
- 97.56
- Mkt cap
- 7.25B
- Vol
- 1.32M
- Avg vol
- 620.55K
- EPS
- 1.32
- P/E
- 69.88
- Div yield
- 0.00%
More statistics
- Low
- 91.25
- High
- 98.48
- Forward P/E
- 42.80
- Beta
- 0.04
- Short ratio
- 6.53
- Inst. own
- 101.26%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 23, 2027
- 50-d avg
- 78.88
- 200-d avg
- 59.94
- 1y target
- 103.63
Financial health
Altman Z-Score
17.54 Safe zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
6 / 9 Average
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
B3 / 5 overall
- DCF 1
- Return on Equity 4
- Return on Assets 5
- Debt / Equity 4
- P/E 1
- P/B 1
Valuation
P/E 51.6×
FY 2016 5y median 5.7× FY 2025
P/S 4.5×
FY 2016 5y median 4.5× FY 2025
P/B 5.4×
FY 2016 5y median 3.2× FY 2025
P/FCF 120×
FY 2016 5y median 93.3× FY 2025
EV/EBITDA 32.1×
FY 2016 5y median -4.5× FY 2025
EV/Sales 4.3×
FY 2016 5y median 4.2× FY 2025
FCF Yield 0.8%
FY 2016 5y median 0.8% FY 2025
Profitability
Gross Margin 54.6%
FY 2016 5y median 79.1% FY 2025
Operating Margin 11.4%
FY 2016 5y median -9.3% FY 2025
Net Margin 8.7%
FY 2016 5y median 5.2% FY 2025
ROE 10.4%
FY 2016 5y median 3.2% FY 2025
ROIC 8.2%
FY 2016 5y median 2.3% FY 2025
ROA 7.7%
FY 2016 5y median 2.7% FY 2025
Growth (YoY)
Revenue 60.1%
FY 2016 FY 2025
Operating Income 269.3%
FY 2016 FY 2025
EPS (diluted) 225.0%
FY 2016 FY 2025
Free Cash Flow 0.0%
FY 2016 FY 2025
Financial Health
Current Ratio 3.8×
FY 2016 5y median 4.3× FY 2025
Quick Ratio 3.4×
FY 2016 5y median 3.9× FY 2025
Debt / Equity 0.0×
FY 2016 5y median 0.0× FY 2025
Net Debt / EBITDA -1.7×
FY 2016 5y median 0.8× FY 2025
Interest Coverage 0.0×
FY 2016 5y median 0.0× FY 2025
Dividends
Dividend Yield 0.0%
FY 2016 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2016 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31